Evidence map›Paper›PMID 37943287›Full record

ArticleESC heart failure2024

Cost-utility of cardiac contractility modulation in patients with heart failure with reduced ejection fraction in Italy.

Maria Lucia Narducci, Mario Cesare Nurchis, Federico Ballacci, Federica Giordano, Giovanna Elisa Calabrò, Massimo Massetti, Filippo Crea, Nadia Aspromonte, Gianfranco Damiani

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06973902 (Advanced Heart Failure), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06973902 recruitingnot on this mapstarted 2025, after this paper: background citation

Advanced Heart Failure: The Predictive Value of Dobutamine Echo-stress in the Clinical Response to Cardiac Contractility Modulation Therapy (CCM)

TypeobservationalSponsorQuovadis AssociazioneRan2025 to 2028Enrolled120ConditionsSymptomatic Congestive Heart FailureArmsCardiac Contractility Modulation (CCM) implant
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Maria Lucia NarducciDepartment of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Mario Cesare NurchisSection of Hygiene, Department of Health Science and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.
Federico BallacciDepartment of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Rome, Italy.ORCID https://orcid.org/0000-0002-0341-1142
Federica GiordanoDepartment of Cardiovascular and Thoracic Sciences, Università Cattolica del Sacro Cuore, Rome, Italy.
Giovanna Elisa CalabròSection of Hygiene, Department of Health Science and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.
Massimo MassettiDepartment of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Filippo CreaDepartment of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Nadia AspromonteDepartment of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Gianfranco DamianiSection of Hygiene, Department of Health Science and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.
Università Cattolica del Sacro Cuore · ITAgostino Gemelli University Polyclinic · IT

Funding

Impulse Dynamics
6 · The paper itself

Abstract

aimsCardiac contractility modulation (CCM) is a device therapy for heart failure, based on the delivery of high-voltage biphasic impulses to the right ventricular septum during the myocardial absolute refractory period. This study evaluated the cost-effectiveness of CCM therapy plus optimal medical therapy (OMT) vs. OMT alone in patients with heart failure with reduced ejection fraction. METHODS AND

resultsA Markov model with a lifespan time horizon was developed to assess the cost-utility using the FIX trials as main data sources. A deterministic sensitivity analysis and a probabilistic sensitivity analysis were run to analyse the decision uncertainty in the model through cost-effectiveness acceptability curve (CEAC) and cost-effectiveness acceptability frontier (CEAF). Value of information analysis was also conducted computing the expected value of perfect information (EVPI) and the expected value of partial perfect information. The base case results showed that the CCM plus OMT option was highly cost-effective compared with OMT alone with an incremental cost-utility ratio of €7034/quality-adjusted life year (QALY). The CEAC and CEAF illustrated that for all willingness to pay levels above €5600/QALY, tested up to €50 000/QALY, CCM plus OMT alternative had the highest probability of being cost-effective. The EVPI per patient was estimated to be €124 412 on a willingness to pay threshold of €30 000/QALY.

conclusionsFor patients with heart failure with reduced ejection fraction, CCM therapy could be cost-effective when taking a lifetime horizon. Further long-term, post-approval clinical studies are needed to verify these results in a real-world context, particularly concerning the effect of CCM therapy on mortality.

Indexed as

Heart FailureCardiotonic AgentsHumansItalyStroke VolumeCardiotonic AgentsCardiac contractility modulationCostsDevice therapyEconomic evaluationHeart failure

Identifiers

PMID37943287
PMCPMC10804153
OpenAlexW4388524497

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.